Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.[1][2]

Ponezumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetbeta-amyloid
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6552H10158N1730O2090S52
Molar mass148272.48 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.[3]

References

edit
  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association.
  2. ^ Popescu CD, Trofin D, Ignat B, Matei D (2014). "New Aspects of Therapeutic Management in Alzheimer`s Disease". In Atta-ur-Rahman (ed.). Frontiers in Clinical Drug Research: Alzheimer Disorders. Vol. 3. Sharjah: Bentham Science Publishers. p. 55. doi:10.2174/9781681080680115030004. ISBN 978-1-68108-068-0.
  3. ^ "Alzforum".